Novo Nordisk strikes gene editing deal with Durham-based Life Edit
Gene editing from a Durham-based firm that will target possible new therapeutics has led to a deal with international drug firm Novo Nordisk worth a potential $2 billion if not more. Here are the details.
Source: wraltechwire.com